Logotype for ARS Pharmaceuticals Inc

ARS Pharmaceuticals (SPRY) investor relations material

ARS Pharmaceuticals Cantor Global Healthcare Conference 2025 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for ARS Pharmaceuticals Inc
Cantor Global Healthcare Conference 2025 summary3 Sep, 2025

Launch progress and market access

  • Ten months into launch, with initial focus on improving access and converting large payers from prior authorization to open access.

  • Direct-to-consumer (DTC) campaign began in May/June, with linear TV ads starting in July, expected to drive uptake.

  • About 10,000 doctors have prescribed the product, with early adopters showing increased prescribing rates over time.

  • Physician adoption is growing as awareness and patient education increase, especially among early adopters.

  • Emphasis on making access easier for doctors and educating patients and caregivers.

Marketing strategy and consumer engagement

  • Jingle-based advertising was chosen over celebrity endorsements for memorability and cost-effectiveness.

  • The campaign slogan "Hello Nephi, Goodbye Needles" highlights the product's unique, needle-free profile.

  • Commercials emphasize device size, convenience, and include a free carry case, with plans to include the case in the product box by end of Q1.

  • Market research shows aided awareness rose from 20% to 49% after the campaign, with positive trends in patient intent to discuss and request prescriptions.

  • The campaign resonates especially with parents and caregivers, focusing on ease of use and reduced anxiety.

Sales dynamics and prescription trends

  • Discontinuation of the GoodRx program in July led to a temporary drop in cash pay prescriptions and market share, but improved overall revenue quality.

  • Cash sales are a small portion of the market and are less profitable; focus is on insured patients and education about the $199 BlinkRx option.

  • Back-to-school season creates a surge in pediatric renewals, but high doctor workload limits new product discussions during this period.

  • About 50% of annual prescriptions are for new patients, with higher renewal rates among children.

  • Average co-pay for the product is $37, lower than generic auto-injectors, with 80% of commercially insured patients paying $25 or less.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next ARS Pharmaceuticals earnings date

Logotype for ARS Pharmaceuticals Inc
Q3 202512 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next ARS Pharmaceuticals earnings date

Logotype for ARS Pharmaceuticals Inc
Q3 202512 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on developing treatments for patients and caregivers affected by severe allergic reactions, including anaphylaxis. The company's flagship product in development is Neffy, a needle-free, low-dose intranasal epinephrine nasal spray designed to offer a safe, effective, and user-friendly alternative to traditional injectable epinephrine devices. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage